Astria Therapeutics (NASDAQ:ATXS) Trading Up 2.9%

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price was up 2.9% during mid-day trading on Tuesday . The stock traded as high as $11.26 and last traded at $11.21. Approximately 110,589 shares traded hands during trading, a decline of 89% from the average daily volume of 980,668 shares. The stock had previously closed at $10.89.

Wall Street Analyst Weigh In

Several analysts have issued reports on ATXS shares. Jefferies Financial Group boosted their price target on Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 25th. Wedbush restated an “outperform” rating and issued a $17.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, March 26th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Astria Therapeutics in a research report on Monday, March 25th.

Astria Therapeutics Price Performance

The company has a market capitalization of $579.20 million, a PE ratio of -4.51 and a beta of 0.69. The business has a 50-day moving average of $13.70 and a 200 day moving average of $9.17.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). As a group, research analysts anticipate that Astria Therapeutics, Inc. will post -1.55 EPS for the current year.

Insider Activity

In other news, Director Perceptive Advisors Llc acquired 2,481,350 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were bought at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the purchase, the director now directly owns 4,873,721 shares in the company, valued at $58,923,286.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Perceptive Advisors Llc acquired 2,481,350 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were bought at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the purchase, the director now directly owns 4,873,721 shares in the company, valued at $58,923,286.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Morabito sold 9,200 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $11.15, for a total value of $102,580.00. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently bought and sold shares of ATXS. FMR LLC lifted its holdings in Astria Therapeutics by 6.7% during the second quarter. FMR LLC now owns 377,445 shares of the biotechnology company’s stock worth $1,132,000 after buying an additional 23,561 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Astria Therapeutics during the 2nd quarter valued at $41,000. Millennium Management LLC purchased a new stake in shares of Astria Therapeutics during the 2nd quarter valued at $51,000. UBS Group AG lifted its holdings in shares of Astria Therapeutics by 12,948.0% during the 3rd quarter. UBS Group AG now owns 3,262 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,237 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in Astria Therapeutics during the 3rd quarter worth about $158,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.